Zefu Liu

Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Correction: The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 27, 2026

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2025

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.

Journal: iMeta

Published: January 29, 2025

Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.

Enhanced Oxidative Phosphorylation Driven by TACO1 Mitochondrial Translocation Promotes Stemness and Cisplatin Resistance in Bladder Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 25, 2024

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 14, 2024

Partial versus radical nephrectomy for the treatment of pT3aN0M0 renal cell carcinoma: A propensity score analysis.

Partial versus radical nephrectomy for the treatment of pT3aN0M0 renal cell carcinoma: A propensity score analysis.

Journal: Asian journal of surgery

Published: November 22, 2022

AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.

AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.

Journal: Nature communications

Published: November 11, 2022

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.

NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.

Journal: Cell reports

Published: October 05, 2022

Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.

Knockdown of ZBTB11 impedes R-loop elimination and increases the sensitivity to cisplatin by inhibiting DDX1 transcription in bladder cancer.

Journal: Cell proliferation

Published: March 09, 2022

Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer.

Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer.

Journal: Oncogene

Published: November 24, 2021

RITA1 drives the growth of bladder cancer cells by recruiting TRIM25 to facilitate the proteasomal degradation of RBPJ.

RITA1 drives the growth of bladder cancer cells by recruiting TRIM25 to facilitate the proteasomal degradation of RBPJ.

Journal: Cancer science

Published: November 18, 2021

MTHFR 677TT is associated with decreased number of embryos and cumulative live birth rate in patients undergoing GnRHa short protocol: a retrospective study.

MTHFR 677TT is associated with decreased number of embryos and cumulative live birth rate in patients undergoing GnRHa short protocol: a retrospective study.

Journal: BMC pregnancy and childbirth

Published: July 01, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026